Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesCryosite Ltd

Cryosite Ltd

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
1.22 AUD 0.00(0%)
Last update at 2026-11-10T23:00:00Z
Market Cap
59.55M
P/E
30.50

Momentum Score

…

Cryosite Limited provides outsourced clinical trials logistic services in Australia. It operates through Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord Blood segments. The Ambient, cold, and frozen segment provides good manufacturing practice (GMP) clinical trial materials, scheduled medicines, controlled drug storage, clinical ancillary supplies, medical devices, and commercial products with strict temperature requirements. The Ultra-frozen and cryogenic segment offers advanced therapy medicinal products (ATMPS), such as cell and gene therapies (CGT), cell therapies, mRNA-based medicines, biological samples, and research and development materials requiring high-integrity cold storage. The Cord Blood segment provides storage of cord blood cell and tissue samples for personal or directed therapeutic use by maintaining under validated chain-of-identity controls. It also offers reverse logistics services, secondary packaging, inventory management, and quality transportation and distribution solutions. Cryosite Limited was incorporated in 1999 and is based in South Granville, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.22
Low
1.22
High
52 Week Price Range
1.00
Low
1.40
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on Cryosite Ltd (ASX: CTE) is limited; it appears to operate in cryogenic storage and sample management for life-science and clinical customers. Long-term growth drivers could include rising demand for biobanking, biologics development and regulated clinical-sample storage, which may benefit specialized cold-chain providers; investors may find exposure to these structural trends attractive if the company can scale.
Key risks include small-company and execution risk, stringent regulatory and compliance requirements for handling clinical samples, capital intensity of cold-chain infrastructure and competition from larger logistics and specialized biobanking firms.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.22
Dividend Yield
-
Revenue TTM
16.70M
Revenue Per Share
0.34
Gross Profit TTM
10.43M
Debt / Equity
1.59
ROE
61.75%
Net Debt
5.47M
ROCE
14.83%
Diluted EPS TTM
0.04

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax 3.15M 2.52M 2.09M 1.57M 1.81M
Net income 2.23M 1.88M 1.84M 1.41M 1.36M
Selling general administrative - 5.47M 5.11M 4.90M 4.29M
Selling and marketing expenses - 0.06M 0.05M 0.06M 0.09M
Gross profit 9.51M 8.89M 7.99M 7.17M 6.84M
Reconciled depreciation - 0.87M 0.79M 0.70M 0.56M
Ebit 3.16M 2.54M 2.25M 1.60M 1.84M
Ebitda 4.07M 3.41M 3.04M 2.30M 2.40M
Depreciation and amortization 0.91M 0.87M 0.79M 0.70M 0.56M
Operating income 3.16M 2.50M 2.05M 1.52M 1.88M
Other operating expenses 13.54M 11.62M 10.56M 0.89M 0.04M
Interest expense 0.34M 0.02M 0.16M 0.03M 0.03M
Tax provision - 0.64M 0.25M 0.17M 0.44M
Interest income - 0.18M 0.20M 0.08M 0.01M
Net interest income - 0.03M 0.03M 0.05M -0.07M
Income tax expense 0.92M 0.64M 0.25M 0.17M 0.44M
Total revenue 16.70M 14.12M 12.61M 11.94M 11.76M
Total operating expenses 6.35M 6.39M 5.94M 5.65M 4.95M
Cost of revenue 7.19M 5.23M 4.62M 4.76M 4.92M
Total other income expense net -0.01M 0.03M 0.03M 0.05M -0.01M
Net income from continuing ops - 1.88M 1.84M 1.41M 1.36M
Net income applicable to common shares - 1.88M 1.84M 1.41M 1.36M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 25.97M 19.46M 19.71M 22.65M 21.50M
Intangible assets 0.01M - - 0.01M 0.01M
Other current assets 0.36M 1.04M 0.44M 1.20M 1.25M
Total liab 21.12M 17.07M 18.26M 19.86M 19.64M
Total stockholder equity 4.85M 2.39M 1.45M 2.78M 1.86M
Deferred long term liab - - - 8.16M 9.35M
Other current liab 1.55M 2.09M 1.06M 0.94M 0.80M
Common stock 3.54M - 3.54M 5.98M 5.98M
Capital stock - 3.54M - 5.98M 5.98M
Retained earnings 1.05M -1.18M -2.09M -3.20M -4.12M
Other liab - - - 13.64M 15.30M
Other assets - - - 9.42M 10.78M
Cash 2.24M 5.06M 4.70M 5.73M 5.34M
Cash and equivalents - - - 5.73M 5.34M
Total current liabilities 4.67M 4.53M 3.99M 3.78M 3.73M
Current deferred revenue 2.01M - 2.10M 2.04M 2.23M
Net debt 5.47M - -2.26M -3.12M -4.49M
Short term debt 0.22M - 0.18M 0.16M 0.23M
Short long term debt total 7.72M - 2.44M 2.61M 0.85M
Other stockholder equity - - - -2.78M -
Property plant equipment - - - 4.04M 2.29M
Total current assets 5.23M 8.87M 6.61M 9.18M 8.30M
Net tangible assets - - - 2.68M 1.74M
Short term investments - - - 1.00M -
Net receivables 2.57M 2.15M 1.41M 1.73M 1.21M
Inventory 0.06M 0.04M 0.06M 0.06M 0.05M
Accounts payable 0.89M 1.07M 0.66M 0.63M 0.46M
Accumulated other comprehensive income 0.26M - - - -
Non currrent assets other 6.19M 6.19M 8.36M 8.36M 9.52M
Non current assets total 20.74M 10.60M 13.10M 13.47M 13.20M
Capital lease obligations - 2.27M - 2.61M 0.85M
Long term debt total - - - 2.44M 0.62M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - -0.42M 0.73M -1.22M -0.86M
Change to liabilities - - - -1.30M -1.31M
Total cashflows from investing activities -10.87M -0.42M 0.73M -1.22M -0.86M
Net borrowings - - - -0.28M -0.29M
Total cash from financing activities 5.33M -1.29M -3.50M -0.80M -0.18M
Change to operating activities - - - 1.18M 1.33M
Net income 2.23M 1.88M 1.84M 1.41M 1.36M
Change in cash -2.82M 0.36M -0.03M -0.61M 1.46M
Begin period cash flow 5.06M 4.70M 4.73M 5.34M 3.88M
End period cash flow 2.24M 5.06M 4.70M 4.73M 5.34M
Total cash from operating activities 2.73M 2.06M 2.74M 1.41M 2.52M
Issuance of capital stock - - - - 0.12M
Depreciation 0.91M - 0.79M 0.65M 0.53M
Other cashflows from investing activities - 0.17M 0.18M 0.08M 0.00M
Dividends paid - -0.98M -0.73M 0.49M 0.49M
Change to account receivables -0.29M - 0.34M -0.53M 0.47M
Sale purchase of stock - - -2.44M - 0.12M
Other cashflows from financing activities -0.32M -0.31M -0.33M -0.31M -0.30M
Change to netincome - - - -0.04M 0.11M
Capital expenditures 10.87M 0.59M 0.45M 0.30M 0.86M
Change in working capital -0.55M - 0.15M -0.53M 0.47M
Stock based compensation - - - - 0.00M
Other non cash items 0.13M 2.06M 2.60M -0.12M 0.63M
Free cash flow -8.14M 1.48M 2.44M 1.11M 1.66M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CTE
Cryosite Ltd		 -
-%		 1.22 30.50 10.47 3.57 12.28 3.89 15.18
SHL
Sonic Healthcare Ltd		 0.09
0.45%		 19.92 16.16 17.21 0.90 1.15 1.36 8.10
IDX
Integral Diagnostics Ltd		 -
-%		 1.70 28.83 15.24 0.82 0.97 1.52 9.49
ACL
Australian Clinical Labs Ltd		 0.01
0.30%		 3.33 26.67 16.84 0.81 3.95 1.24 5.12
HLS
Healius Ltd		 0.01
2.86%		 0.54 - 29.24 0.26 2.08 0.94 10.14

Profile*

Cryosite Ltd

Cryosite Limited provides outsourced clinical trials logistic services in Australia. It operates through Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord Blood segments. The Ambient, cold, and frozen segment provides good manufacturing practice (GMP) clinical trial materials, scheduled medicines, controlled drug storage, clinical ancillary supplies, medical devices, and commercial products with strict temperature requirements. The Ultra-frozen and cryogenic segment offers advanced therapy medicinal products (ATMPS), such as cell and gene therapies (CGT), cell therapies, mRNA-based medicines, biological samples, and research and development materials requiring high-integrity cold storage. The Cord Blood segment provides storage of cord blood cell and tissue samples for personal or directed therapeutic use by maintaining under validated chain-of-identity controls. It also offers reverse logistics services, secondary packaging, inventory management, and quality transportation and distribution solutions. Cryosite Limited was incorporated in 1999 and is based in South Granville, Australia.

13a Ferndell Street, South Granville, NSW, Australia, 2142

61 2 8865 2000

https://www.cryosite.com

27

Name Title Year Born
Mr. John Hogg Chief Exec. Officer NA
Ms. Jane Hao Chief Financial Officer NA
Ms. Kim Bradley-Ware B.Com., CPA, L.L.B. Company Sec. NA
Mr. John Hogg CMILT CEO, MD & Director NA
Mr. Jon Stearns Operations Manager NA
Ms. Alicia Steel Chief Quality Officer NA
Mr. Dray Andrea Company Secretary NA
Mr. John Hogg CMILT CEO, MD & Director NA
Mr. Jon Stearns Operations Manager NA
Ms. Alicia Steel Chief Quality Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…